Diuretic Strategy and Decongestion in Heart Failure

Definition and pathophysiology

Congestion is a central expression of the heart-failure syndrome and reflects excessive retention of sodium and water, with expansion of both the intravascular and extravascular compartments. Heart failure is defined physiologically by the inability of the heart to provide blood flow appropriate to tissue requirements unless filling pressures are elevated. Consequently, congestion may occur across the full range of left-ventricular ejection fraction and may result from systolic dysfunction, diastolic dysfunction, or both.

The clinical consequences of extracellular volume expansion include elevated cardiac filling pressures, pulmonary congestion, systemic venous hypertension, and peripheral interstitial edema. These abnormalities produce breathlessness, orthopnea, weight gain, peripheral edema, early satiety, abdominal distension and, in some patients, bendopnea. Congestion may also aggravate functional mitral regurgitation, ventricular dilatation, myocardial wall stress and subendocardial ischemia.

Neurohormonal activation and vascular and renal abnormalities contribute to sodium and water retention. The interaction between cardiac and renal dysfunction is particularly important. Cardiorenal syndrome may develop during acute decompensated heart failure, but worsening renal function does not necessarily indicate reduced cardiac output or impaired renal perfusion. Many patients have preserved cardiac output; increased venous and intra-abdominal pressures, impaired renal venous outflow and persistent right-sided congestion may be important mechanisms.

Diuretics relieve the hemodynamic consequences of congestion by producing a negative sodium and water balance. They can reduce jugular venous pressure, pulmonary congestion, peripheral edema and body weight, often within days. However, diuretic treatment has not been shown formally to reduce heart-failure mortality; its established role is symptom relief and prevention of recurrent congestion and hospitalization.

Clinical presentation and symptoms

Symptoms of congestion

Dyspnea is the dominant presenting symptom in acute decompensated heart failure and occurs in more than 90% of patients presenting with the syndrome. Its severity and temporal pattern vary considerably.

Symptoms of systemic venous congestion include:

• Peripheral edema

• Rapid weight gain

• Increasing abdominal girth

• Early satiety

• Bendopnea

• Abdominal ascites

Older patients may present atypically, with fatigue, depression, sleep disturbance or altered mental status rather than prominent breathlessness.

Hemodynamic phenotypes

Initial assessment should distinguish congestion from hypoperfusion. This distinction provides a practical framework for selecting treatment:

Right-ventricular failure is characterized by increased right-atrial and right-ventricular pressures with systemic congestion. Interventricular dependence may impair left-ventricular filling and reduce systemic output. In this setting, venous congestion is generally treated initially with diuretics, whereas norepinephrine and/or inotropes are reserved for low output and hemodynamic instability.

Evaluation and physical examination

The objective of decongestion is clinical euvolemia rather than an isolated numerical change in weight. Assessment should integrate the history, physical examination, laboratory data and diagnostic testing.

Examination for congestion

Useful bedside indicators of persistent or improving congestion include:

• Jugular venous pressure

• Pulmonary rales

• Presence or disappearance of an S3 gallop

• Peripheral edema

• Hepatomegaly

• Abdominal ascites

• Respiratory symptoms and orthopnea

• Body weight

Normalization of the jugular venous pressure, clearing of pulmonary rales, disappearance of gallop sounds and resolution of edema, hepatomegaly and ascites support effective decongestion.

Weight is widely used as a practical surrogate for fluid removal, but it may be difficult to interpret and does not necessarily correlate closely with clinical outcomes. Conversely, residual congestion at discharge is strongly associated with recurrent decompensation and rehospitalization.

Assessment of perfusion

The examination should also identify hypoperfusion and end-organ compromise. The source material describes cardiogenic shock as a state associated with hypotension, peripheral vasoconstriction, cyanosis, mental confusion and oliguria. In patients with acute heart failure, congestion and impaired perfusion may coexist, and this combination requires more intensive management than congestion alone.

Diagnostics

Electrocardiography

The source material does not provide a specific electrocardiographic diagnostic strategy for diuretic treatment or decongestion.

Chest imaging

Chest radiography may demonstrate pulmonary congestion. Lung ultrasound, chest radiography and natriuretic peptides are discussed as tools for early diagnosis of acute heart failure, but the source material does not provide a detailed imaging algorithm or specific diagnostic thresholds for decongestion.

Echocardiography

Echocardiographic assessment is relevant to establishing the underlying heart-failure phenotype and left-ventricular ejection fraction. Heart failure with an ejection fraction greater than 40% includes heart failure with mildly reduced and preserved ejection fraction. Structural heart disease and ejection fraction help support the diagnosis, while natriuretic peptides and associated conditions such as atrial fibrillation and obesity may provide additional diagnostic information.

The source material does not specify echocardiographic criteria for monitoring response to diuretic therapy.

Invasive hemodynamics

Pulmonary artery catheterization can measure left-ventricular filling pressure and estimate cardiac output. It may be useful in patients with hypotension or clinical evidence of heart failure when the hemodynamic profile is uncertain. Invasive arterial pressure monitoring permits calculation of systemic vascular resistance, which can guide vasopressor and vasodilator therapy.

Some patients have markedly elevated left-ventricular filling pressures with preserved cardiac index, whereas others have relatively low filling pressures with reduced cardiac index. The former generally benefit from diuresis; the latter may respond to volume expansion. Thus, clinical congestion should not be inferred solely from cardiac output, and treatment should be guided by the combined assessment of filling pressures, perfusion and volume status.

Remote pulmonary arterial pressure monitoring can be used as a surrogate of left-sided filling pressure. Pressure-guided adjustment of heart-failure therapy, particularly diuretic therapy, has been associated with fewer heart-failure hospitalizations and improved outcomes in patients with reduced and preserved ejection fraction.

Biomarkers and laboratory findings

Natriuretic peptides

Natriuretic peptides support the diagnosis and risk assessment of heart failure. Elevated concentrations may assist in identifying heart failure with preserved or mildly reduced ejection fraction. In acute decompensated heart failure, discharge natriuretic peptide concentrations are associated with subsequent mortality and rehospitalization.

Serial changes may also be informative. The source material describes associations between natriuretic peptide responses and outcomes in chronic heart failure with reduced ejection fraction, including changes after initiation of sacubitril/valsartan. Interpretation requires awareness that treatment can influence measured peptide concentrations.

Renal function

Renal function should be assessed throughout the heart-failure trajectory and during active decongestion. Approximately 30% of patients hospitalized with acute decompensated heart failure have abnormal renal function at baseline; this is associated with longer hospitalization and increased mortality.

Worsening renal function during treatment requires interpretation in relation to residual congestion. Persistent venous congestion may be more clinically important than an isolated reduction in glomerular filtration rate. The source material does not support abandoning effective diuresis solely because renal function worsens, particularly when filling pressures and clinical congestion remain elevated.

Electrolytes and acid–base status

Diuretic therapy may produce electrolyte and acid–base abnormalities. Sequential nephron blockade with a thiazide-type diuretic increases the risk of significant hypokalemia. Routine laboratory monitoring should therefore include renal function and serum electrolytes during intensified therapy. The source material does not provide a complete electrolyte-monitoring schedule or specific replacement protocols.

Sodium

Hyponatremia is associated with natriuretic peptide elevation and adverse outcomes in acutely decompensated heart failure. Tolvaptan is discussed particularly in the setting of hyponatremia and volume overload, but the source material does not provide a general correction protocol or detailed safety-monitoring schedule.

Iron deficiency and anemia

Anemia and hematinic deficiency are common in chronic heart failure. Intravenous iron therapies, including ferric carboxymaltose and ferric derisomaltose, have been evaluated in patients with heart failure and iron deficiency. The source material indicates potential benefits in clinical status, quality of life and heart-failure events, but does not provide diagnostic thresholds or dosing regimens.

Treatment and management

Acute decongestion

Intravenous loop diuretics

Intravenous loop diuretics are the cornerstone of treatment when acute heart failure is accompanied by congestion. They rapidly relieve symptoms and are particularly important when oral absorption is impaired.

The optimal regimen is individualized. Trials comparing high- with low-dose therapy and bolus with continuous infusion have not established a universally superior approach. A continuous infusion may be considered when high doses are required or when intermittent boluses provide inadequate or inconsistent diuresis.

Treatment should continue until clinical euvolemia has been achieved. The response should be assessed through symptoms, urine output, weight, physical examination, renal function and electrolytes rather than through weight change alone.

Escalation for inadequate response

If congestion persists, the loop-diuretic dose should be increased and/or a second diuretic class added. Sequential nephron blockade can be achieved with a thiazide-type drug such as chlorothiazide or metolazone. This approach may enhance natriuresis and facilitate decongestion but increases the risk of marked hypokalemia and requires close laboratory surveillance.

Acetazolamide may be added to loop diuretic therapy in acute decompensated heart failure with volume overload. It facilitates greater decongestion, but available evidence does not demonstrate a reduction in heart-failure readmission or mortality.

High-dose spironolactone in acute heart failure did not improve the primary natriuretic peptide endpoint or secondary clinical outcomes in the cited study. Accordingly, escalation of mineralocorticoid receptor antagonist therapy should not be assumed to substitute for an effective loop-diuretic strategy.

Vasodilators

Agents with vasodilator properties may reduce preload and congestion, but the source material indicates a lack of convincing evidence for routine intravenous vasodilator use in emergency-department patients with acute heart failure. Vasodilators must be used cautiously because hypotension may be serious.

Nitrates reduce preload through venodilation without directly reducing total plasma volume. They may be useful when congestive symptoms are prominent, but blood pressure must be monitored carefully.

Inotropes and vasopressors

Inotropes should be considered when congestion is accompanied by hypoperfusion, particularly when low output produces organ dysfunction. Inotropic agents may worsen arterial hypotension and may therefore require combination with norepinephrine.

In isolated right-ventricular failure, norepinephrine and/or inotropes are indicated when low cardiac output and hemodynamic instability are present. Agents that reduce filling pressures may be preferred in selected situations, including levosimendan and phosphodiesterase type III inhibitors.

Short-term positive inotropy has not produced consistent long-term benefit in chronic heart failure. Acute use is therefore reserved for selected patients with hypoperfusion or hemodynamic instability rather than routine treatment of congestion.

Renal replacement therapy and ultrafiltration

Ultrafiltration is an invasive method of fluid removal that can supplement pharmacologic therapy. Its theoretical advantages include controlled fluid removal and reduced electrolyte depletion. However, in patients with acute decompensated heart failure and worsening renal function, stepped pharmacologic therapy produced similar weight loss with fewer adverse events than ultrafiltration; ultrafiltration was associated with rises in serum creatinine and more complications, including kidney failure, bleeding and catheter-related events.

Ultrafiltration should therefore not be used as the primary strategy in patients who respond to diuretics. Its role as rescue treatment in diuretic-refractory patients with advanced renal disease remains uncertain and should be considered judiciously.

Chronic volume management

Loop diuretics

Most symptomatic patients with heart failure require loop diuretics to maintain sodium balance and euvolemia. This is particularly important in heart failure with reduced ejection fraction, where diuretics should be combined with guideline-directed medical therapy rather than used as a replacement for neurohormonal antagonists.

Chronic oral loop-diuretic therapy is appropriate for most patients at discharge to maintain decongestion. Torsemide has greater oral bioavailability and a longer half-life than furosemide, but the cited randomized trial did not demonstrate a mortality or morbidity advantage for torsemide.

Foundational heart-failure therapy

Diuretics treat congestion but do not replace therapies intended to prevent disease progression. In symptomatic heart failure with reduced ejection fraction, the treatment strategy combines diuretics for salt and water retention with foundational therapies that limit adverse remodeling and improve long-term outcomes.

For heart failure with preserved or mildly reduced ejection fraction, decongestion with diuretics remains a major component of management. SGLT2 inhibitors have demonstrated benefit across the ejection-fraction spectrum and are described as standard-of-care therapy for heart failure with preserved and reduced ejection fraction. Patients with mildly reduced ejection fraction may also benefit from therapies used in reduced ejection fraction, including renin–angiotensin–aldosterone system blockade and sacubitril/valsartan.

Tolvaptan

Tolvaptan can produce greater weight loss and net fluid loss in selected patients with acute heart failure and volume overload. However, studies cited in the source material did not show consistent early dyspnea benefit, and treatment was associated in one study with a greater likelihood of worsening renal function. Its role is therefore selective, particularly in patients with hyponatremia or difficult volume management, rather than routine replacement of loop diuretics.

Predischarge and transition planning

The transition from intravenous to oral diuretics is a critical stage in care. Continued need for parenteral diuresis is a major reason for prolonged hospitalization, and the patient should be assessed for:

• Resolution of clinical congestion

• Stability on an oral diuretic regimen

• Renal function and electrolyte safety

• Optimization of guideline-directed therapy

• Tolerability of chronic medications

• Readiness for outpatient follow-up

Persistent congestion at discharge predicts a high risk of rehospitalization. Predischarge natriuretic peptide measurement may assist in evaluating residual risk and the adequacy of decongestion.

An acute hospitalization should also be used to optimize chronic heart-failure therapy. The source material emphasizes that the episode represents an opportunity to initiate or intensify guideline-directed treatment, rather than merely treating the immediate fluid overload.

Guideline recommendations

The source material supports the following principles:

• Use loop diuretics as first-line therapy for clinically congested acute heart failure.

• Treat congestion even when it occurs in the absence of reduced ejection fraction.

• Combine diuretics with guideline-directed medical therapy in heart failure with reduced ejection fraction.

• Escalate the loop-diuretic dose and/or combine diuretic classes when congestion persists.

• Monitor renal function and electrolytes during intensified diuresis, particularly when thiazide-type agents are added.

• Continue decongestion until euvolemia is achieved whenever possible, because residual congestion is associated with recurrent decompensation.

• Reserve inotropes and vasopressors for hypoperfusion, low output or hemodynamic instability rather than routine treatment of congestion.

• Avoid routine primary ultrafiltration in diuretic-responsive patients with acute decompensated heart failure.

• Optimize chronic oral and device therapy before discharge and coordinate transition to outpatient care.

• Consider SGLT2 inhibitors across the spectrum of ejection fraction, with particular relevance to heart failure with preserved and mildly reduced ejection fraction.

Prognosis and follow-up

Decompensated heart failure carries substantial early and long-term morbidity. Rehospitalization and mortality remain high, particularly when congestion persists after treatment. Discharge natriuretic peptide concentrations and residual clinical congestion identify patients at increased postdischarge risk.

Follow-up should focus on maintaining euvolemia, detecting recurrent congestion early, reassessing renal function and electrolytes, and ensuring that guideline-directed therapies are initiated and appropriately optimized. The transition from acute to chronic care should be deliberate, with reassessment of symptoms, examination findings, oral diuretic requirements and treatment tolerability.

Remote pulmonary arterial pressure monitoring may support outpatient adjustment of therapy, with diuretic modification being the principal therapeutic consequence. Its use has been associated with fewer heart-failure hospitalizations and improved outcomes in patients with both reduced and preserved ejection fraction.

Because acute heart failure is heterogeneous, outcomes are unlikely to improve through a uniform treatment approach alone. Effective care depends on matching the intensity and type of decongestion to the patient’s degree of congestion, perfusion, renal status and response to treatment, while using the hospitalization to establish a durable chronic-management plan.